PRKCE

Protein kinase C epsilon type · Q02156 · PRKCE on Sugi Atlas →

99,192 patent compounds predicted against PRKCE, 72,406 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Balanol (SCHEMBL62128)	1.00	19/20
Balanol (SCHEMBL62129)	1.00	19/20
Staurosporine (SCHEMBL8156)	1.00	9/20
Staurosporine (SCHEMBL8157)	1.00	9/20
SCHEMBL100287	0.44	8/20
SCHEMBL117745	0.56	7/20
Fasudil (SCHEMBL4674)	1.00	6/20
SCHEMBL115053	0.56	6/20
Phorbol Myristate Acetate (SCHEMBL115567)	1.00	5/20
SCHEMBL9306	0.89	5/20
SCHEMBL78989	0.62	5/20
Phorbol (SCHEMBL72895)	0.62	5/20
SCHEMBL123495	1.00	4/20
SCHEMBL123496	1.00	4/20
SCHEMBL9305	0.74	4/20
SCHEMBL82376	0.63	4/20
Phorbol (SCHEMBL64353)	0.62	4/20
Phorbol (SCHEMBL14937)	0.60	4/20
Daph (SCHEMBL11017)	1.00	3/20
Cinnamtannin B1 (SCHEMBL94430)	1.00	3/20

Clinical trials — most relevant to PRKCE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
PKC412 and 5-Azacytidine	PHASE1/PHASE2	COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer	PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	PHASE2	COMPLETED
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL	PHASE1/PHASE2	NOT_YET_RECRUITING
Metformin and Simvastatin Use in Bladder Cancer	PHASE2	UNKNOWN
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer	PHASE1	WITHDRAWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Possible Diagnostic Protein Markers in Schistosoma Related Bladder Diseases.	nan	NOT_YET_RECRUITING
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Novel Inhibitors of Lipolysis in the Treatment of Lipid a Glucose Metabolism in Obstructive Sleep Apnea Syndrome	nan	UNKNOWN
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH	nan	COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Effect of Age on Glucose and Lipid Metabolism	nan	COMPLETED
Fat Induced Insulin Resistance and Atherosclerosis	nan	COMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PRKCE binder may also engage these)

Protein	Name	Similarity
P10830	—	1.000	P10830 →
P09216	—	1.000	P09216 →
P16054	—	1.000	P16054 →
P34885	—	1.000	P34885 →
P13678	—	1.000	P13678 →
Q16975	—	0.998	Q16975 →
PRKCD	Protein kinase C delta type	0.997	landscape →
P09215	—	0.996	P09215 →
Q5PU49	—	0.995	Q5PU49 →
PRKCH	Protein kinase C eta type	0.995	landscape →
PRKCA	Protein kinase C alpha type	0.994	landscape →
Q02111	—	0.994	Q02111 →
Q64617	—	0.993	Q64617 →
P23298	—	0.993	P23298 →
PRKCB	Protein kinase C beta type	0.993	landscape →
Q16974	—	0.992	Q16974 →
P10102	—	0.992	P10102 →
P05128	—	0.992	P05128 →
P05130	—	0.991	P05130 →
P13677	—	0.991	P13677 →
P05696	—	0.991	P05696 →
P63318	—	0.991	P63318 →
P63319	—	0.991	P63319 →
P90980	—	0.990	P90980 →
PRKCQ	Protein kinase C theta type	0.990	landscape →
P04409	—	0.990	P04409 →
Q4R4U2	—	0.989	Q4R4U2 →
A8KBH6	—	0.989	A8KBH6 →
P10829	—	0.989	P10829 →
P20444	—	0.989	P20444 →